约３３％服用特罗凯无效且从未吸过烟的肺腺癌患者具有ALK阳性

行动矮人

据Dr West 介绍，在所有非小细胞肺癌患者中，具有ALK阳性的只有约4-5％；而对于一个服用特罗凯无效且从未吸过烟的肺腺癌患者，他／她有三分之一的可能具有EML4-ALK突变（ALK阳性）。也就是说，可以服用克里唑替尼。这个比例很高了。

下面是他的原话：

＂If tarceva proves to be unhelpful, never-smokers with an adenocarcinoma are the patients most likely to have an EML4-ALK mutation (about a third vs. only about 4-5% of the wider NSCLC population), but testing for that would make EGFR testing seem easy.  Right now, it's not commercially available but will be offered at centers that are participating in the trials with the ALK inhibitor PF-02341066 (an investigational agent, if the cryptic name didn't give that away).  We're activating that trial in October, and I'm anxious to have both the agent and the test available for my handful of patients who I'd expect to have a pretty high probability of having an EML4-ALK mutation.＂

Believem

就算可以服用，费用也是很大的问题

流浪四方

这个得顶下，我也感觉易，特无效的腺癌患者ALK突变的概率还可以，但从不知道这样一个确切的数字。

小米288

药太贵了而且国内还买不到。π_π　无奈！